Mechanistic Study of Ocrevus

University of Michigan35 enrolled

Overview

The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Sclerosis

Interventions

OcrelizumabDRUG

Description Needed

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Patients with MS either with relapsing or primary progressive course; who are newly starting on ocrelizumab (Ocrevus) at the time of enrollment OR Healthy controls who do not have a significant medical conditions such as cancer, chronic infection, or autoimmune disease, have not taken steroids in the past 2 months, and who are not on an immune suppressant medication. * Ability to give informed consent * Willing to have blood drawn as scheduled in the protocol * Willing and able to complete all procedures and evaluations related to the study Exclusion Criteria: * Medical or psychiatric conditions that may affect the patient's ability to give informed consent * Has received an experimental drug within 30 days of enrollment * Concomitant other disease modifying medications (such as Rebif, Betaseron, Avonex, Copaxone, Gilenya, Tecfidera, Aubagio, Mayzent, Mavenclad, Alemtuzumab, methotrexate, azathioprine, Novantrone, cyclophosphamide, cyclosporine, Tysabri, Rituxan, Ocrevus, etc.) * Has any contraindication to high-dose immunotherapy, including pregnancy, trying to become pregnant, or breast feeding during the study * Active hepatitis B virus infection * History of life-threatening infusion reaction to Rituxan or Ocrevus * Chronic infection or any severe acute infection within 3 months prior to screening

Locations (1)

University of Michigan

Ann Arbor, Michigan, United States

Outcomes

Primary Outcomes

Change in frequency of regulatory B cells

Percentage B cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls

Time frame: From baseline to 24 months

Secondary Outcomes

Change in frequency of T cell subtypes

Percentage of T cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls

Time frame: From baseline to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.